NIDA offers this grant to accelerate medication development for Substance Use Disorders (SUDs). This grant advances compounds towards FDA approval by leveraging NIDA funds with external organizations or significant resource commitments from single entities. Its purpose is to overcome resource limitations and significantly increase the pace of SUD medication development. Projects can range from new molecular entities to expanded clinical indications, requiring defined entry/exit points for FDA advancement. NIDA provides up to $2,000,000 direct costs annually for up to three years.
Opportunity ID: 240181
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-13-334 |
| Funding Opportunity Title: | Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 19, 2013 |
| Last Updated Date: | Aug 11, 2014 |
| Original Closing Date for Applications: | Sep 07, 2016 |
| Current Closing Date for Applications: | Sep 07, 2016 |
| Archive Date: | Oct 08, 2016 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $3,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Small businesses State governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments Public and State controlled institutions of higher education Independent school districts County governments Public housing authorities/Indian housing authorities Special district governments Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | NIDA grant-funded research programs aiming to develop medications for the treatment of Substance Use Disorders (SUDs) are often hindered by a lack of both human and financial resources.Drug development is a lengthy process that requires a wide range of skill sets.Consequently, individual grantees with the necessary expertise in one area of medications development are often unable to advance a project through the next stage because of a lack of real world experience in the development process and/or the financial resources to advance a medication through the development pipeline in an acceptable timeframe. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outsideorganizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat SUDs move through the drug development process.Both the term (up to three years) and budget (up to $2,000,000/year in direct costs) of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding.Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project must have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process.It is hoped that support for these collaborations will accelerate the rate of medications development for Substance Use Disorders. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-13-334.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| This funding opportunity has had its budgetary limits increased per NOT-DA-14-027. | Aug 11, 2014 | |
| Aug 11, 2014 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-13-334 |
| Funding Opportunity Title: | Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 19, 2013 |
| Last Updated Date: | Aug 11, 2014 |
| Original Closing Date for Applications: | Sep 07, 2016 |
| Current Closing Date for Applications: | Sep 07, 2016 |
| Archive Date: | Oct 08, 2016 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $3,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Small businesses State governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments Public and State controlled institutions of higher education Independent school districts County governments Public housing authorities/Indian housing authorities Special district governments Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | NIDA grant-funded research programs aiming to develop medications for the treatment of Substance Use Disorders (SUDs) are often hindered by a lack of both human and financial resources.Drug development is a lengthy process that requires a wide range of skill sets.Consequently, individual grantees with the necessary expertise in one area of medications development are often unable to advance a project through the next stage because of a lack of real world experience in the development process and/or the financial resources to advance a medication through the development pipeline in an acceptable timeframe. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outsideorganizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat SUDs move through the drug development process.Both the term (up to three years) and budget (up to $2,000,000/year in direct costs) of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding.Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project must have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process.It is hoped that support for these collaborations will accelerate the rate of medications development for Substance Use Disorders. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-13-334.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-13-334 |
| Funding Opportunity Title: | Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 11, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 07, 2016 |
| Archive Date: | Oct 08, 2016 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $2,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts Private institutions of higher education State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public and State controlled institutions of higher education Small businesses City or township governments Special district governments Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | NIDA grant-funded research programs aiming to develop medications for the treatment of Substance Use Disorders (SUDs) are often hindered by a lack of both human and financial resources.Drug development is a lengthy process that requires a wide range of skill sets.Consequently, individual grantees with the necessary expertise in one area of medications development are often unable to advance a project through the next stage because of a lack of real world experience in the development process and/or the financial resources to advance a medication through the development pipeline in an acceptable timeframe. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outsideorganizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses.Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat SUDs move through the drug development process.Both the term (up to three years) and budget (up to $2,000,000/year in direct costs) of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding.Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project must have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process.It is hoped that support for these collaborations will accelerate the rate of medications development for Substance Use Disorders. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-13-334.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | FORMS-C | Forms-C | PKG00183510 | Feb 27, 2014 | May 17, 2016 | View |
| FORMS-D | Use for due dates on or after May 25, 2016 | PKG00223531 | Jun 28, 2016 | Sep 07, 2016 | View |
Package 1
Mandatory forms
240181 RR_SF424_2_0-2.0.pdf
240181 PHS398_ResearchPlan_2_0-2.0.pdf
240181 PHS398_CoverPageSupplement_2_0-2.0.pdf
240181 RR_KeyPersonExpanded_2_0-2.0.pdf
240181 RR_OtherProjectInfo_1_3-1.3.pdf
240181 PerformanceSite_2_0-2.0.pdf
Optional forms
240181 RR_SubawardBudget30_1_3-1.3.pdf
240181 PlannedReport-1.0.pdf
240181 PHS398_CumulativeInclusionReport-1.0.pdf
240181 PHS398_ModularBudget_1_2-1.2.pdf
240181 RR_Budget_1_3-1.3.pdf
Package 2
Mandatory forms
240181 RR_SF424_2_0-2.0.pdf
240181 PHS398_CoverPageSupplement_3_0-3.0.pdf
240181 RR_OtherProjectInfo_1_3-1.3.pdf
240181 PerformanceSite_2_0-2.0.pdf
240181 RR_KeyPersonExpanded_2_0-2.0.pdf
240181 PHS398_ResearchPlan_3_0-3.0.pdf
Optional forms
240181 RR_Budget_1_3-1.3.pdf
240181 RR_SubawardBudget30_1_3-1.3.pdf
240181 PHS398_ModularBudget_1_2-1.2.pdf
240181 PHS_Inclusion_Enrollment_Report-1.0.pdf
240181 PHS_AssignmentRequestForm-1.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
